Corporate Magazine 2012 - Boehringer Ingelheim

THERAPEUTIC AREA (TA) REVIEW CORE TEAMThe TA Review core team, which worked for over nine months in across-functional effort on the development of the Disease Map2025 defining potential future focus areas for our R&D+M efforts.THE FUTURE OF OUR RESEARCHAND DEVELOPMENTWe remain strongly committed to creating real value for patientsby constantly developing medicines in areas of high unmet medicalneed. We continuously review the focus of our Prescription Medicinesbusiness at the disease and indication level in oder to chart ourdirection in a rapidly changing external environment.Disease Map 2025The Disease Map 2025 defines goalsand key areas in research, developmentand medicine (R&D+M) in which wewant to develop our Prescription Medicines(PM) business. While the adjustmentof our research focus is ongoing,we at the same time make investmentsin R&D+M that are above the industryaverage.GOAL: BRINGING NEWMEDICINES TO PATIENTSThe Disease Map 2025 will helpus to achieve our goal of bringingnew medicines to patients. In orderto effectively and efficientlyenable this, we have defined specificactions for our establishedtherapeutic areas as well as areasof cross-TA opportunities.A cross-functional team reviewed ourfuture aspirations in the PM businessdivision by considering patients’ andsocietal needs for better medicines.Emphasis was placed on fundamentaltrends, unique opportunities andspecial challenges for our established,emerging and potential new researchareas.The results of this review have helpedus to draft the Disease Map 2025,which provides recommendationson our future direction.By assessing a large number of diseases,we were able to prioritise the most attractiveopportunities for our portfolio.These include diseases that are alreadypart of our current R&D focus as wellas new diseases. For both current andnew diseases, the target product profiles(TPPs) are very ambitious, with a strongemphasis on disease modification oversymptomatic treatment.Disease-modifying approachesWithin the therapeutic areas the emphasiswill be placed on disease-modifyingapproaches in larger and establishedindications. Furthermore, we willcontinue to focus on accessing external60 Boehringer Ingelheim annual report 2012